Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

1(25%)

Results Posted

200%(2 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_3

25%

Ph phase_1

25%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

2(50.0%)

Phase 3Large-scale testing

1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Terminated(2)

Detailed Status

Withdrawn1

Active, not recruiting1

Terminated1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (25.0%)

Phase 22 (50.0%)

Phase 31 (25.0%)

Trials by Status

withdrawn125%

active_not_recruiting125%

terminated125%

completed125%

Recent Activity

1 active trials

Showing 4 of 4

active_not_recruitingphase_1

CP101 for the Treatment of Ulcerative Colitis

NCT05852574

terminatedphase_3

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

NCT05153499

completedphase_2

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

NCT03497806

withdrawnphase_2

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)

NCT03829878

Clinical Trials (4)

Showing 4 of 4 trials

NCT05852574Phase 1

CP101 for the Treatment of Ulcerative Colitis

Active Not Recruiting

NCT05153499Phase 3

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

Terminated

NCT03497806Phase 2

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Completed

NCT03829878Phase 2

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4